Physician profile
Robert Adair
NPI 1457467862
$4,258.65
in general payments reported to CMS, 2019-2025
34 companies · $931 in 2025
The $931 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $444 · 2021: $665 · 2022: $363 · 2023: $267 · 2024: $630 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $640.30 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $448.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $387.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.16 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $296.33 | 2019-2023 | Xarelto |
| Almatica Pharma LLC | $278.32 | 2023-2025 | Loreev Xr, Gralise |
| Abbvie INC. | $231.47 | 2021-2024 | Linzess, Viberzi |
| Amgen INC. | $196.34 | 2023-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $165.07 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.43 | 2019-2024 | Xifaxan |
| Allergan, INC. | $151.36 | 2019-2020 | |
| Pfizer INC. | $144.94 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.78 | 2021-2025 | |
| Amarin Pharma, INC. | $90.63 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $66.02 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $65.30 | 2019-2020 | |
| Astellas Pharma US INC | $60.63 | 2019-2025 | Veozah |
| Gilead Sciences, INC. | $45.66 | 2019 | |
| Exact Sciences Corporation | $45.41 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $43.84 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $37.90 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $26.38 | 2019-2020 | |
| Dexcom, INC. | $25.27 | 2024 | Dexcom G6 Transmitter |
| Arbor Pharmaceuticals, INC. | $22.77 | 2020 | |
| Sunovion Pharmaceuticals INC. | $21.96 | 2022 | |
| Vivus LLC | $20.80 | 2022 | |
| Ironwood Pharmaceuticals, INC | $20.58 | 2020 | |
| Sumitomo Pharma America, INC. | $18.96 | 2025 | Gemtesa |
| Genentech USA, INC. | $17.50 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.23 | 2025 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.90 | 2022 | |
| Esperion Therapeutics, INC. | $14.13 | 2022 | |
| Abbott Laboratories | $13.75 | 2024 | Eterna |
| Nestle Healthcare Nutrition INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Adair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.